Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control
Authors
Keywords
-
Journal
Blood Cancer Journal
Volume 7, Issue 3, Pages e549-e549
Publisher
Springer Nature
Online
2017-03-31
DOI
10.1038/bcj.2017.27
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
- (2016) P. Sonneveld et al. BLOOD
- The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma
- (2016) C. Pawlyn et al. CLINICAL CANCER RESEARCH
- Targeting EZH2 in cancer
- (2016) Kimberly H Kim et al. NATURE MEDICINE
- Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
- (2015) Brian A. Walker et al. JOURNAL OF CLINICAL ONCOLOGY
- Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation
- (2015) Zheng Zhou et al. LEUKEMIA & LYMPHOMA
- EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes
- (2015) H. Hernando et al. MOLECULAR CANCER THERAPEUTICS
- The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors
- (2015) Daniel Zingg et al. Nature Communications
- Curing myeloma at last: defining criteria and providing the evidence
- (2014) B. Barlogie et al. BLOOD
- Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia
- (2014) B. Xu et al. BLOOD
- EZH2 Inhibitor Efficacy in Non-Hodgkin’s Lymphoma Does Not Require Suppression of H3K27 Monomethylation
- (2014) William D. Bradley et al. CHEMISTRY & BIOLOGY
- Inhibiting Enhancer of Zeste Homolog 2 Promotes Cellular Senescence in Gastric Cancer Cells SGC-7901 by Activation of p21 and p16
- (2014) Jie Bai et al. DNA AND CELL BIOLOGY
- The H3K27me3 demethylase UTX in normal development and disease
- (2014) Joni Van der Meulen et al. Epigenetics
- A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma
- (2014) Eileen M. Boyle et al. GENES CHROMOSOMES & CANCER
- Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
- (2014) S. K. Knutson et al. MOLECULAR CANCER THERAPEUTICS
- Prognostic Value of Polycomb Proteins EZH2, BMI1 and SUZ12 and Histone Modification H3K27me3 in Colorectal Cancer
- (2014) Anne Benard et al. PLoS One
- Aberrant promoter methylation of p15 INK4b and p16 INK4a genes may contribute to the pathogenesis of multiple myeloma: a meta-analysis
- (2014) Xuan Wang et al. TUMOR BIOLOGY
- Current and potential epigenetic targets in multiple myeloma
- (2014) Charlotte Pawlyn et al. Epigenomics
- Clinicopathological significance and potential drug target of p15INK4B in multiple myeloma
- (2014) Jun Li et al. Drug Design Development and Therapy
- Histone Methyltransferase MMSET/NSD2 Alters EZH2 Binding and Reprograms the Myeloma Epigenome through Global and Focal Changes in H3K36 and H3K27 Methylation
- (2014) Relja Popovic et al. PLoS Genetics
- An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1
- (2013) Kyle D. Konze et al. ACS Chemical Biology
- EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation
- (2013) Wendy Béguelin et al. CANCER CELL
- NSD2 Is Recruited through Its PHD Domain to Oncogenic Gene Loci to Drive Multiple Myeloma
- (2013) Z. Huang et al. CANCER RESEARCH
- Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment
- (2013) G. J. Morgan et al. CLINICAL CANCER RESEARCH
- A TC classification-based predictor for multiple myeloma using multiplexed real-time quantitative PCR
- (2013) M F Kaiser et al. LEUKEMIA
- EZH2 in normal and malignant hematopoiesis
- (2013) K Lund et al. LEUKEMIA
- Transcriptional regulation by Polycomb group proteins
- (2013) Luciano Di Croce et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- MMSET is the key molecular target in t(4;14) myeloma
- (2013) F Mirabella et al. Blood Cancer Journal
- Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial
- (2012) G. J. Morgan et al. BLOOD
- EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
- (2012) K. Xu et al. SCIENCE
- Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival
- (2011) K. D. Boyd et al. CLINICAL CANCER RESEARCH
- Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results
- (2011) G. J. Morgan et al. HAEMATOLOGICA
- A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial
- (2011) K D Boyd et al. LEUKEMIA
- EZH2-Dependent Suppression of a Cellular Senescence Phenotype in Melanoma Cells by Inhibition of p21/CDKN1A Expression
- (2011) T. Fan et al. MOLECULAR CANCER RESEARCH
- NSD2 Links Dimethylation of Histone H3 at Lysine 36 to Oncogenic Programming
- (2011) Alex J. Kuo et al. MOLECULAR CELL
- The Polycomb complex PRC2 and its mark in life
- (2011) Raphaël Margueron et al. NATURE
- Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy
- (2010) F. van Rhee et al. BLOOD
- Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma
- (2010) B. A. Walker et al. BLOOD
- Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma
- (2010) D. Hose et al. HAEMATOLOGICA
- Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
- (2010) Ryan D Morin et al. NATURE GENETICS
- Polycomb Target Genes Are Silenced in Multiple Myeloma
- (2010) Antonia Kalushkova et al. PLoS One
- Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells
- (2009) W. Fiskus et al. BLOOD
- Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer
- (2009) Gijs van Haaften et al. NATURE GENETICS
- MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells
- (2008) J. L.R. Brito et al. HAEMATOLOGICA
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started